Loading...
Loading...
VRNA| Name | Value |
|---|---|
| Revenues | 103.1M |
| Cost of Revenue | 4.8M |
| Gross Profit | 98.4M |
| Operating Expense | 85.1M |
| Operating I/L | 13.3M |
| Other Income/Expense | -1.4M |
| Interest Income | 4.3M |
| Pretax | 11.9M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | 11.9M |
Verona Pharma plc is a clinical stage biopharmaceutical company specializing in the development and commercialization of therapies for respiratory diseases. The company's primary product candidate, ensifentrine, is an inhaled dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes, designed to act as both a bronchodilator and an anti-inflammatory agent. Currently in Phase 3 clinical trials, ensifentrine targets chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company is focused on developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler, to address unmet medical needs in the respiratory disease market.
